Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Summary

This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus

Timeline

Start

2015-05-14

Primary completion

2016-08-26

Completion

2017-03-27

Outcome

Met primary endpoint

registry analysis (superiority or other test); Empagliflozin 10 mg/Linagliptin 5 mg vs Linagliptin 5 mg + Placebo 10 mg; p <0.0001; Adjusted Mean Difference (Net) -1.14 (95% CI -1.36 to -0.91); Mixed Models Analysis NCT02453555 ↗

Publications

• Kawamori R, Haneda M, Suzaki K, Cheng G, Shiki K, Miyamoto Y, Solimando F, Lee C, Lee J, George J. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. Diabetes Obes Metab. 2018 Sep;20(9):2200-2209. doi: 10.1111/dom.13352. Epub 2018 Jun 1.

Drugs

Indications